Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

NCT07407933 is registered in ClinicalTrials.gov with MediLink Therapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT07407933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07407933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 31, 2026
Completion date
February 28, 2029
Enrollment
118 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

thoracic neoplasms, lung diseases, small cell lung carcinoma